Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepBTer phase 2a trial of terbinafine in chronic hepatitis B
NL-OMON59002Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Terbinafine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Decline in serum HBsAg and Decline in serum HBV DNA in group A. Started Jul 2024; status: completed.
02
Drugs
Terbinafine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON59002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59002.